Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
e000783
However, there are a few exceptions to this regulation
Important topics include: Potential drug interactions between GLP-1 medications and DMARDs Monitoring strategies for both conditions Whether weight loss might improve RA symptoms or treatment response Cardiovascular risk reduction strategies Safety considerations including contraindications (personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Patients should not discontinue or modify DMARD therapy based on unproven theories about GLP-1 medications treating RA
Community reports suggest approximately 60% better outcomes with the combination compared to either peptide individually
Health 24, 1455
